(NASDAQ: SVRA) Savara's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.92%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.62%.
Savara's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast SVRA's revenue for 2026 to be $3,346,122,810, with the lowest SVRA revenue forecast at $2,594,282,199, and the highest SVRA revenue forecast at $4,097,963,421. On average, 3 Wall Street analysts forecast SVRA's revenue for 2027 to be $15,502,780,556, with the lowest SVRA revenue forecast at $7,397,420,262, and the highest SVRA revenue forecast at $30,141,030,828.
In 2028, SVRA is forecast to generate $22,997,680,841 in revenue, with the lowest revenue forecast at $15,341,005,197 and the highest revenue forecast at $35,400,458,364.